1-溴-4-环戊氧基苯 | 30752-30-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-溴-4-环戊氧基苯
• 英文名称: 4-bromophenylcyclopentyl ether
• 英文别名: 1-bromo-4-(cyclopentyloxy) benzene；p-Brom-phenyl-oxy-cyclopentan；4-bromophenoxycyclopentane；1-bromo-4-cyclopentoxybenzene；1-Bromo-4-(cyclopentyloxy)benzene；1-bromo-4-cyclopentyloxybenzene
• CAS: 30752-30-8
• 化学式: C₁₁H₁₃BrO
• 分子量: 241.128
• InChiKey: DWMSXAAIGFYBGC-UHFFFAOYSA-N

物化性质

• 沸点：
  296.7±13.0 °C(Predicted)
• 密度：
  1.382±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  1-溴-4-环戊氧基苯 在 正丁基锂 、 三氟乙酸 作用下， 以 乙醚 、 正己烷 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-(4-cyclopentyloxyphenyl)-1,2,3,6-tetrahydropyridine
  参考文献：
  名称：

  Synthesis and biological evaluation of new 4-arylpiperidines and 4-aryl-4-piperidinols: dual Na+ and Ca2+ channel blockers with reduced affinity for dopamine D2 receptors

  摘要：

  A series of novel 4-arylpiperidines and 4-aryl-4-piperidinols (2a-f, 3a f and 4a-f) wits synthesized and evaluated for blocking effects on both neuronal Na+ and T-type Ca2+ channels and binding affinity for dopamine D-2 receptors. Most or the compounds blockaded both ion channels with potency greater than or equal to flunarizine Ia which was adopted as a reference standard. In addition, these compounds had significantly reduced affinity for dopamine D-2 receptors which is common in this class of structure. Compounds 2a-f, 3a-f and 4a-f exhibited potent anticonvulsant effects following systemic (ip) administration on audiogenic seizures in DBA/2 mice, indicating their excellent brain permeability. The neuroprotective activity of 2a, 3a and 4a was also assessed in a transient middle cerebral artery Occlusion (MCAO) model. These Compounds significantly reduced neuronal damage without affecting ischemic hyperthemia, while flunarizine Ia produced only minor reductions. In particular. 4a had 1.7-fold the potency in this MCAO model but only 1/20 the affinity for dopamine D-2 receptors of 1a. The Superposition of 2a, 3a and 4a on the basis of analyses of systematic conformation and similar structure has revealed that the cinnamyl, phenacyl and phenoxy-propanol groups are likely to be structurally and biologically equivalent. Moreover, the Superposition of 2a and 2f shows that diphenyl ether and biphenyl groups occupy a similar space, suggesting that both groups act as a bioisostere for the blockade of ion channels: however, this is not the case for dopamine D-2 receptors since only biphenyl Compounds such as 2f had high affinity similar to flunarizine Ia. Compound 4a (SUN N5030) has a good pharmacological profile and may be Useful in the alleviation and treatment or ischemic diseases. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00288-7
• 作为产物：
  描述：

  4-溴苯酚 、 环戊醇 在 偶氮二甲酸二异丙酯 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 以81%的产率得到1-溴-4-环戊氧基苯
  参考文献：
  名称：

  Base catalyzed Mitsunobu reactions as a tool for the synthesis of aryl sec-alkyl ethers

  摘要：

  A facile and versatile method for the synthesis of aryl sec-alkyl ethers from phenols with alcohols in the presence of base via a Mitsunobu reaction is described. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2007.02.072

文献信息

• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2017214505A1

  公开（公告）日：2017-12-14

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物、以及使用这种化合物治疗或预防与酶神经鞘糖脂转移酶（CGT）相关的疾病或紊乱的方法，例如溶酶体贮积症。溶酶体贮积症的例子包括 Krabbe 病和白质变性白血病。
• 2-PYRIDONE COMPOUNDS
  申请人：KAWAGUCHI Takanori

  公开号：US20110237791A1

  公开（公告）日：2011-09-29

  A 2-pyridone compound represented by the formula [1]: wherein in the formula [1], the ring represented by A represents a benzene ring or a pyridine ring, X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, and W represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)}, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.

  化学式为[1]所代表的2-吡啶酮化合物： 其中在化学式[1]中， 由A代表苯环或吡啶环表示的环， X代表下面所示的化学式[3]所代表的任意结构： V代表单键或较低的烷基链，以及 W代表单键、醚键或较低的烷基链（其中较低的烷基链可能含有醚键）}， 该化合物的异构体或立体异构体，其药学上可接受的盐，或其溶剂化合物是一种具有出色的GK激活效果并且可用作药物的化合物。
• HETEROCYCLIC COMPOUNDS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20210094973A1

  公开（公告）日：2021-04-01

  The invention provides new heterocyclic compounds having the general formula (I) wherein A, L 1 , X, m, n and R 1 to R 4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  这项发明提供了具有一般式(I)的新杂环化合物，其中A、L1、X、m、n和R1至R4如本文所述，包括这些化合物的组合物、制造这些化合物的方法以及使用这些化合物的方法。
• New azetidine derivatives, pharmaceutical compositions and uses thereof
  申请人：FLECK Martin

  公开号：US20130172316A1

  公开（公告）日：2013-07-04

  The invention relates to new azetidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  该发明涉及新的氮杂环丙烷衍生物的公式I及其用作药物的用途，以及用于它们的治疗用途的方法和含有它们的药物组合物。